论文部分内容阅读
应用HAART法治愈需要73年Siliciano JD,Kajdas J,Finzi D,et al长期随访研究证实了静止期CD4~+ T淋巴细胞作为HIV-1病毒宿主的稳定性。(Nature Med,2003,9:727~728) 这是Hopkins研究组关于HIV病毒宿主的一份报告。既往一个连续3年治疗观察的研究显示,静止期CD4~+ T淋巴细胞作为HIV的宿主细胞稳定性极强。病人接受HAART治疗,病毒被很好控制后,其体内的静止期CD4~+ T淋巴细胞半寿期可达44个月。这份报告应用同样的技术测量了62个HIV阳性患者体内病毒的衰变率,这批患者病毒抑制长达7
Long-term follow-up of Siliciano JD, Kajdas J, Finzi D, et al 73 years after HAART treatment is required confirms the stability of quiescent CD4 ~ + T lymphocytes as HIV-1 host. (Nature Med, 2003, 9: 727-728) This is a report by the Hopkins Study Group on HIV virus hosts. A previous study of 3 consecutive years of treatment showed that resting CD4 + T lymphocytes are highly stable as host cells for HIV. Patients receiving HAART treatment, the virus is well controlled, its quiescent CD4 ~ + T lymphocyte half-life of up to 44 months. The report uses the same technique to measure the rate of virus decay in 62 HIV-positive patients, with virus suppression up to 7